(RENE.L) ReNeuron Group PLC Buy/Sell

RNS Number : 2388B ReNeuron Group plc 22 October 2009

PRESS RELEASE

ReNeuron to present ReN001 stroke programme at Royal Society of Medicine briefing

Guildford, UK, 22 October 2009: ReNeuron Group plc (LSE: RENE.L) announces that it will present its approach to the treatment of disabled stroke patients with its ReN001 stem cell therapy at the Royal Society of Medicine's 10th Medical Innovations Briefing to be held in London on the evening of 27 October 2009.

The presentation will describe ReNeuron's ReN001 stroke therapy and aspects of the proposed Phase I clinical trial with ReN001, for which UK regulatory and conditional ethical approvals were obtained earlier this year. The briefing will be given by the Principal Investigator for the Phase I trial, Professor Keith Muir, SINAPSE Professor of Clinical Imaging, Division of Clinical Neurosciences at the University of Glasgow, and Dr John Sinden, Chief Scientific Officer of ReNeuron.

The proceedings will be filmed and made available via the websites of ReNeuron and the Royal Society of Medicine in due course.

Enquiries:

Michael Hunt, Chief Executive Officer +44 (0) 1483 302560

Dr John Sinden, Chief Scientific Officer ReNeuron Group plc

Jonathan Birt, Susan Quigley +44 (0) 20 7831 3113

Financial Dynamics

Simon Leathers +44 (0) 20 7776 6550

Daniel Stewart & Company plc

Alastair Stratton, Tim Graham +44 (0) 20 3206 7000

Matrix Corporate Capital LLP

Carmel Turner +44 (0) 20 7290 2900

Royal Society of Medicine

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The

Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS The company news service from the London Stock Exchange

MSCBDBDGRSDGGCD

RNS Number : 1106A ReNeuron Group plc 02 October 2009

PRESS RELEASE

ReNeuron announces publication of new research using ReNcell® stem cell products

Guildford, UK, 2 October 2009: ReNeuron Group plc (LSE: RENE.L) announces the recent publication of new research using its ReNcell® neural stem cell products. These human cell lines and supporting products are marketed through US-based Millipore Corporation for academic and commercial research.

Researchers from the University of California, San Diego School of Medicine and the Salk Institute for Biological Studies, La Jolla, California have developed a safe strategy for reprogramming cells to a pluripotent state without the use of the potentially harmful viral delivery mechanisms or genomic insertions that were necessary in earlier cell reprogramming studies conducted elsewhere. In the study, researchers were able to reprogramme ReNeuron's ReNcell®VM cell line using a single factor to generate stable human induced pluripotent stem cells (iPS cells), similar to human embryonic stem cells with the ability to differentiate into any type of cell in the body. The current excitement surrounding iPS cells lies in their potential to circumvent the need to extract such pluripotent stem cells from the early human embryo, as is the case with human embryonic stem cells.

The research paper describes the ReNcell®VM cell line used in the study as representing a reliable, homogenous and commercially available tool to dissect the individual factors required for cell reprogramming, and a potentially better standard model for fundamental cell reprogramming studies than human primary fibroblasts, a cell type typically used in this type of research. Moreover, the paper describes the reprogramming strategy used in the study, due to its lack of viral or transgene interference with the cells, as representing a safe way to generate iPS cells for potential clinical use as well as basic research.

The research, led by UCSD Stem Cell Program researcher Alysson Muotri, PhD, assistant professor in the Departments of Pediatrics at UC San Diego and Rady Children's Hospital, San Diego and UCSD's Department of Cellular and Molecular Medicine, was published in the on-line journal, PLoS One in September (Marchetto, M.C.N. et al. (2009) PLoS ONE 4(9), e7076). Dr John Sinden, Chief Scientific Officer of ReNeuron, said: "This latest publication is a clear example of how ReNeuron's ReNcell® lines can be successfully used at the very cutting edge of stem cell research. In this study, the ReNcell®VM cell line was proven to be efficient in generating stable iPS cells at a significantly higher frequency than that obtained using human primary fibroblasts. Furthermore, the study showed for the first time that the iPS cells generated carried a transcriptional "signature" of the original ReNcell® donor cells, raising interesting questions as to what effects, if any, this "memory retention" might have.

"We are delighted to work with Millipore to make these valuable stem cell research tools available to the scientific community."

Enquiries:

Michael Hunt, Chief Executive Officer +44 (0) 1483 302560

Dr John Sinden, Chief Scientific Officer ReNeuron Group plc

Jonathan Birt, Susan Quigley +44 (0) 20 7831 3113

Financial Dynamics

Simon Leathers +44 (0) 20 7776 6550

Daniel Stewart & Company plc

Alastair Stratton, Tim Graham +44 (0) 20 3206 7000

Matrix Corporate Capital LLP

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

About Millipore

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, Millipore collaborates with customers to confront the world's challenging human health issues. From research to development to production, Millipore's scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit http://www.millipore.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS The company news service from the London Stock Exchange

MSCEAFEFEANNFAE

RNS Number : 2187Z ReNeuron Group plc 17 September 2009

PRESS RELEASE

Results of 2009 Annual General Meeting

Guildford, UK, 17 September 2009: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today's 2009 Annual General Meeting were passed.

Enquiries:

Michael Hunt, Chief Executive Officer Dr John Sinden, Chief Scientific Officer ReNeuron Group plc
+44 (0) 1483 302560

Jonathan Birt, Susan Quigley
Financial Dynamics +44 (0) 20 7831 3113

Simon Leathers
Daniel Stewart & Company plc +44 (0) 20 7776 6550

Alastair Stratton, Tim Graham
Matrix Corporate Capital LLP +44 (0) 20 3206 7000

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS The company news service from the London Stock Exchange

RAGUBVWRKRRKARR

STOCKS NEWS Reuters Results diary
Europe Real-time Equity News
UK Stocks on the move
UK smallcaps UK smallcaps news

07:55GMT 17Sep2009-ReNeuron falls on later-than-expected trial date

Shares in stem cell specialist ReNeuron tumble 16 percent after the company says in an update ahead of its AGM that it expects to start its first human trial in late 2009 or early 2010, later than investors had anticipated.
"There's a delay compared to what the market was expecting," says analyst Vadim Alexandre at house brokerage Daniel Stewart, adding that it is good news, however, that the company is now able to announce a specific timeline.
To see ReNeuron's statement please click on

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net
07:43GMT 17Sep2009-Antofagasta up on Cazenove upgrade

Shares in Antofagasta gain 1.2 percent in a strong mining sector, outperforming a 0.7 percent rise by the FTSE, as Cazenove upgrades the Chilean copper miner to "outperform" from "in line".
Cazenove sees a positive outlook for copper prices, to which it says Antofagasta has the highest earnings leverage in the broker's coverage universe.
"We like the fact it is on the cusp of delivering 55 percent production growth over the next two years into what could be very tight copper markets in 2010-11," the broker says in a note.
The broker also sees low delivery risk to the firm's growth, substantial hidden value within the company and an impressive free cash flow generation and potential for capital returns at the year-end.

Reuters Messaging rm://harpreet.bhal.reuters.com@reuters.net
07:20GMT 17Sep2009-Innovation up on contract win

Shares in Innovation Group Plc rise 11 percent to 12.6 pence after the software firm says it signed a contract worth a minimum of 3.7 million pounds with a "large UK retail bank" for both a software licence and services.
The company says the software licence element underpins current year expectations.
"We had been nervous about the outcome for FY2009 estimates, but a series of contract wins over recent months has served to underpin current year forecasts," says analyst Jonathan Imlah of Altium Securities.
Imlah raises the price target on the stock to 12 pence from 10 pence.
To see Innovation's statement please click on

Reuters messaging rm://tresa.sherin.reuters.com@reuters.net
07:13GMT 17Sep2009-Renovo slumps as bid talks fail

Shares in British anti-scarring company Renovo fall by 10 percent after it announces that it has failed to reach a takeover deal.
"Removal of the bid speculation means that Renovo is likely to continue to be weak near term as 'fast money' exits," says Ian Wainwright, managing director of specialist life sciences sales at brokerage Canaccord Adams, in an email.
To see the full article please click on

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net

Keywords: MARKETS UK STOCKSNEWS/

COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.